Compare PCRX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | ARCT |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 194.1M |
| IPO Year | 2011 | N/A |
| Metric | PCRX | ARCT |
|---|---|---|
| Price | $26.30 | $6.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $32.86 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 916.7K | 829.5K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $716,791,000.00 | $97,601,000.00 |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $9.53 | N/A |
| P/E Ratio | $55.91 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $18.17 | $5.85 |
| 52 Week High | $27.64 | $24.17 |
| Indicator | PCRX | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 64.48 | 35.49 |
| Support Level | $25.48 | $6.38 |
| Resistance Level | $27.16 | $7.76 |
| Average True Range (ATR) | 1.00 | 0.43 |
| MACD | 0.15 | 0.20 |
| Stochastic Oscillator | 77.18 | 24.87 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.